The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused
by myxomatous mitral valve disease (MMVD).
This groundbreaking study sought to answer a key question: Can pimobendan — with proven efficacy in treating dogs with congestive heart failure (CHF) caused
by myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?
In the VetSCOPE Study, pimobendan rapidly improved the quality of life in dogs with CHF caused
by myxomatous mitral valve disease (MMVD).
In the QUEST Study, pimobendan significantly increased the survival time of dogs with congestive heart failure (CHF) caused
by myxomatous mitral valve disease (MMVD).
Not exact matches
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused
by naturally occurring
myxomatous mitral valve disease: the QUEST Study.
Mitral regurgitation (MR), secondary to
myxomatous mitral valve disease (MMVD), is the most common cardiac disorder in dogs and is usually caused
by progressive degeneration of the atrioventricular valves.
Myxomatous degeneration of the mitral valve (MMVD) accounts for nearly 75 percent of all heart problems seen
by veterinarians, making it the most common heart disease diagnosed in dogs.
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused
by naturally occurring
myxomatous mitral valve disease: the QUEST study.